Catalog No.
Product Name
Application
Product Information
Citations
-
RIPK1 Inhibitor
Ocadusertib is a selective inhibitor of receptor-interacting protein kinase 1 (RIPK1), which plays a crucial role in cell survival and necroptosis signaling pathways. This compound is utilized in research applications investigating the regulation of programmed cell death and inflammation. Ocadusertib may provide insights into therapeutic strategies for diseases associated with dysregulated RIPK1 activity. -
RIPK3 Inhibitor
RIPK3-IN-1 is a selective inhibitor of receptor-interacting protein kinases 3 (RIPK3), functioning as a type II DFG-out inhibitor with an IC50 of 9.1 nM. This compound also exhibits inhibitory activity against RIPK1 and RIPK2, with IC50 values of 5.5 μM and >10 μM, respectively. Additionally, RIPK3-IN-1 serves as a c-Met kinase inhibitor, demonstrating an IC50 of 1.1 μM. It is suitable for studies related to necroptosis, cell signaling pathways, and cancer research applications. -
RIPK1 Inhibitor
Sibiriline is a selective competitive inhibitor of receptor-interacting protein kinase 1 (RIPK1), specifically targeting its ATP-binding site to stabilize the enzyme in an inactive state. This compound effectively inhibits TNF-induced RIPK1-dependent necroptosis and apoptosis, while sparing caspase-dependent apoptosis. Additionally, Sibiriline has demonstrated protective effects in murine models of concanavalin A-induced hepatitis, highlighting its potential for research in immune-mediated liver injury and related therapeutic applications. -
RIPK1 Inhibitor
RIPK1-IN-26 is a potent inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1), exhibiting strong anti-necroptosis activity. This compound displays favorable metabolic stability and binding specificity in murine models. Its unique properties make RIPK1-IN-26 a valuable tool for investigating potential therapeutic applications in neurodegenerative disorders and developing PET imaging probes. -
RIPK1 Inhibitor
RIPK1-IN-23 is a selective inhibitor of Receptor Interacting Protein Kinase 1 (RIPK1), exhibiting potent anti-necroptotic effects with an EC50 of 1.7 nM in HT-29 cells. This compound also demonstrates significant anti-inflammatory activity, making it a valuable tool for investigating necroptosis and its associated inflammatory pathways in various biological research applications. -
RIPK1 Inhibitor
RIPK1-IN-18 sulfate hydrate is a highly selective inhibitor of receptor-interacting protein kinase 1 (RIPK1), a key regulator of cell death and inflammation. Its potent inhibitory activity makes it a valuable reagent for research focused on autoimmune diseases, providing insights into the mechanistic pathways involved in such conditions. Additionally, RIPK1-IN-18 can be used to investigate the therapeutic potential of targeting RIPK1 in various inflammatory disorders. -
PROTAC-based RIP2 inhibitor
RIPK2-IN-2 is a PROTAC-based inhibitor specifically targeting RIP2 kinase. It effectively inhibits RIP2-dependent proinflammatory signaling pathways, thereby regulating RIP2 activity implicated in autoinflammatory diseases. This compound serves as a valuable tool for research in understanding the molecular mechanisms of inflammation and developing potential therapeutic strategies for related disorders. -
RIPK1 Inhibitor
RIPK1-IN-15 is a potent inhibitor of Receptor Interacting Protein Kinase 1 (RIPK1). This compound demonstrates significant potential in modulating pathways associated with neurodegenerative, autoimmune, and inflammatory diseases. Research applications include the investigation of cell death signaling, inflammation regulation, and therapeutic approaches targeting RIPK1-mediated pathologies. -
RIPK2/ALK2 Inhibitor
RIPK2-IN-1 is a selective inhibitor targeting RIPK2 and ALK2, with an IC50 of 51 nM and 5 nM, respectively. This compound demonstrates substantial efficacy in modulating RIPK2/NOD2 pathways, exhibiting an IC50 of 390 nM in cellular assays. RIPK2-IN-1 is suitable for research applications investigating pathways related to inflammation and immune response mechanisms. -
RIPK1 Inhibitor
RIPK1-IN-39 is a selective inhibitor of receptor-interacting protein kinase 1 (RIPK1), exhibiting an IC50 value of 69.40 nM and more than 100-fold selectivity over RIPK3 (IC50 = 6946 nM). This compound effectively prevents necroptosis in HT-22 and HT-29 cell lines by inhibiting the phosphorylation and activation of the RIPK1-RIPK3-MLKL signaling pathway. Additionally, RIPK1-IN-39 has demonstrated neuroprotective effects in a rat model of middle cerebral artery occlusion (MCAO), making it a valuable tool for research in acute ischemic stroke (AIS). -
RIPK2 Inhibitor
RIPK2-IN-8 is a selective inhibitor of Receptor-interacting protein kinase 2 (RIPK2) with an IC50 of 11 nM. It shows significant selectivity for RIPK2 over RIPK1 (IC50 > 30,000 nM) and a moderate inhibitory effect on RIPK3 (IC50 = 44.61 nM). By inhibiting the NOD2-RIPK2 signaling pathway, RIPK2-IN-8 reduces the expression of key inflammatory cytokines such as IL-6 and TNFα, demonstrating robust anti-inflammatory properties. Its efficacy in an acute liver injury model indicates potential applications in liver injury and inflammation research. -
RIPK1 Inhibitor
RIPK1-IN-21 is a selective inhibitor of receptor-interacting protein kinase 1 (RIPK1), exhibiting an EC50 value of 14.8 nM. This compound is valuable for research into neurodegenerative, autoimmune, and inflammatory diseases, where modulation of RIPK1 activity may play a critical role. Its potent inhibitory effects enable investigations into the mechanisms of RIPK1-mediated cell death and inflammation. -
RIPK1 Modulator
RIPK1-IN-31 is a selective allosteric modulator of receptor-interacting protein kinase 1 (RIPK1) with an IC50 value of 16 nM. This compound demonstrates potential for modulating RIPK1 activity, making it a valuable tool for research in the fields of infectious, autoimmune, and neurodegenerative diseases. Its ability to selectively influence RIPK1 pathways can aid in elucidating the mechanisms underlying these conditions. -
RIPK2 Inhibitor
RIPK2-IN-3 is a potent inhibitor of Receptor Interacting Protein Kinase 2 (RIPK2), demonstrating an IC50 of 6.39 μM against recombinant truncated RIPK2. This compound is utilized in research studies focused on inflammation and cancer, providing valuable insights into the pathways regulated by RIPK2. Its specificity makes it a useful tool for evaluating RIPK2's role in various biological processes. -
RIPK1 Inhibitor
RIPK1-IN-14 is a selective inhibitor of receptor-interacting protein kinase 1 (RIPK1) with an IC50 value of 92 nM. This compound demonstrates significant anti-necroptotic effects in a necroptosis model utilizing U937 cells. RIPK1-IN-14 is applicable in research focusing on cell death mechanisms, inflammation, and neurodegenerative diseases. -
RIPK1 Inhibitor
RIPK1-IN-28 is a potent inhibitor of receptor-interacting protein kinase 1 (RIPK1). It demonstrates significant biological activity with IC50 values of 0.4 nM and 1.2 nM against human I2.1 and Hepa1-6 cell lines, respectively. This compound is valuable for research applications aimed at elucidating the role of RIPK1 in cell death and inflammatory processes. -
RIPK1 Inhibitor
RIPK1-IN-12 is a potent inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1). It effectively inhibits necroptosis, with EC50 values of 1.6 nM in human cells and 2.9 nM in mouse cells. This compound is valuable for research applications focused on cell death pathways and related diseases such as neurodegeneration and cancer. -
RIPK1 Inhibitor
RIPK1-IN-11 is a potent and orally active inhibitor of receptor-interacting protein kinase 1 (RIPK1), demonstrating a Kd of 9.2 nM and an IC50 of 67 nM. This compound effectively inhibits necroptosis in human and mouse cells, with an EC50 range of 17-30 nM. Due to its anti-inflammatory properties, RIPK1-IN-11 is valuable in researching the pathophysiology of inflammatory diseases and cell death mechanisms. -
RIPK1 Inhibitor
RIPK1-IN-38 is a potent, orally active inhibitor of receptor-interacting protein kinase 1 (RIPK1), with an IC50 value of 27 nM. It effectively blocks the phosphorylation of RIPK1 and its downstream effectors, RIPK3 and MLKL, thereby exhibiting significant anti-necroptotic activity. This compound demonstrates strong anti-inflammatory effects in models of systemic inflammatory response syndrome (SIRS) and graft-versus-host disease (GVHD). RIPK1-IN-38 is suitable for research into inflammatory and immune-related diseases. -
RIPK1 Inhibitor
RIPK1-IN-13 is a potent inhibitor of receptor-interacting protein kinase 1 (RIPK1), exhibiting an IC50 value of 1139 nM. By inhibiting RIPK1, this compound effectively disrupts the necroptosis pathway, making it a valuable tool for investigating the molecular mechanisms underlying inflammatory diseases. Its applications extend to various research areas focused on cell death and inflammatory processes. -
RIPK1 Inhibitor
RIPK1-IN-18 is a selective inhibitor of Receptor-Interacting Protein Kinase 1 (RIPK1). It demonstrates potent activity in modulating cell death and inflammation pathways, making it a valuable tool for investigating the underlying mechanisms of autoimmune diseases. This compound is applicable in research focused on therapeutic strategies for conditions associated with RIPK1-mediated signaling. -
RIPK1 Inhibitor
RIPK1-IN-37 is a selective inhibitor of receptor-interacting protein kinase 1 (RIPK1), which plays a crucial role in apoptosis and inflammation. This compound serves as a ligand for the target protein in the PROTAC LD5097 synthesis, facilitating targeted protein degradation research. Its application extends to studies of cell death pathways and the development of novel therapeutics for diseases involving dysregulated RIPK1 activity. -
RIPK1 Inhibitor
RIPK1-IN-34 is a selective inhibitor of receptor-interacting protein kinase 1 (RIPK1) with an IC50 of 126.70 nM, demonstrating significant potency and minimal off-target effects on RIPK3 (IC50 > 10,000 nM). This compound provides substantial neuroprotection by preventing the phosphorylation of key proteins involved in the necroptosis pathway, including RIPK1, RIPK3, and MLKL. Notably, RIPK1-IN-34 exhibits neuroprotective effects in the rat middle cerebral artery occlusion (MCAO) model, making it a valuable tool for research focused on mitigating damage in acute ischemic stroke (AIS). -
RIPK1 Inhibitor
RIPK1-IN-16 is a potent, orally active inhibitor of Receptor-Interacting Protein Kinase 1 (RIPK1). It effectively mitigates excessive inflammation by blocking RIPK1-mediated necroptosis. This compound demonstrates protective effects in mouse models against tumor necrosis factor (TNF)-induced systemic inflammatory response syndrome and sepsis, making it a valuable tool for research into inflammatory diseases and cell death pathways. -
RIPK1 Kinase Inhibitor
RIPK1-IN-20 is a potent inhibitor targeting RIPK1 kinase, exhibiting significant enzymatic inhibition with an IC50 value of 59.8 nM. This compound effectively blocks TNFα-induced necroptosis in both human and murine cells, demonstrating EC50 values ranging from 1.06 to 4.58 nM. It serves as a valuable tool for research into cell death pathways and therapeutic interventions in necroptotic diseases. -
RIPK1 Inhibitor
RIPK1-IN-9 is a selective inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1). It demonstrates potent inhibitory activity in U937 cells with an IC50 of 2 nM, and in L929 cells with an IC50 of 1.3 nM. This compound is valuable for research in cell death, inflammation, and various diseases where RIPK1 is implicated. -
RIPK1 Inhibitor
RIPK1-IN-10 is a potent inhibitor of receptor-interacting protein kinase 1 (RIPK1), a key regulator of cellular apoptosis and necroptosis. This compound is designed for use in biological research applications, particularly in studies focused on cell death pathways, inflammatory responses, and neurodegenerative diseases. Its inhibition of RIPK1 provides a valuable tool for investigating the therapeutic potential of modulating necroptotic processes in various disease models. -
RIPK1 Inhibitor
RIPK1-IN-19 is a selective inhibitor of receptor-interacting protein kinase 1 (RIPK1), exhibiting an IC50 of 15 nM. It demonstrates significant protective effects in models of systemic inflammatory response syndrome (SIRS) induced by TNFα, as well as in imiquimod-induced psoriasis models. This compound serves as a valuable tool for investigating the roles of RIPK1 in inflammation and immune system disorders. -
RIPK1 Kinase Inhibitor
KWCN-41 is a selective inhibitor of RIPK1 kinase, exhibiting an IC50 value of 88 nM. This compound specifically targets and inhibits cell necrosis while leaving apoptotic pathways unaffected. Additionally, KWCN-41 demonstrates anti-inflammatory properties, making it a valuable tool for research in cell death mechanisms and inflammation-related studies. -
RIPK1 Inhibitor
RIPK1-IN-24 is a selective inhibitor of receptor-interacting protein kinase 1 (RIPK1) with an IC50 value of 1.3 μM. This compound is utilized in research investigating the role of RIPK1 in inflammatory diseases, making it a valuable tool for studies on cell survival, apoptosis, and signal transduction pathways. Researchers can leverage RIPK1-IN-24 to elucidate the mechanisms underlying inflammation-related pathologies and explore potential therapeutic strategies. -
RIPK1 Inhibitor
RIPK1-IN-35 is a selective and orally bioavailable inhibitor of receptor-interacting protein kinase 1 (RIPK1) with an IC50 of 5.33 nM. This compound exhibits a strong protective effect against necroptosis in both human and murine cell models. It demonstrates significant therapeutic potential in experimental models of TNF-α-induced systemic inflammatory response syndrome and DSS-induced inflammatory bowel disease. RIPK1-IN-35 is valuable for research into inflammatory diseases associated with necroptosis. -
RIP3 Inhibitor
RIPK3-IN-2 is a selective inhibitor of receptor-interacting protein kinase 3 (RIPK3), which plays a crucial role in necroptotic cell death pathways. This compound is utilized in research focused on diseases associated with activated necroptosis, providing insights into the underlying mechanisms of cellular pathology and potential therapeutic interventions. Its ability to modulate RIPK3 activity makes it a valuable tool for studying necrotic processes in various biological contexts. -
RIPK1 Inhibitor
RIPK1-IN-8 is a selective inhibitor of receptor-interacting protein kinase 1 (RIPK1), exhibiting a potent inhibitory activity with an IC50 value of 4 nM. This compound is valuable for research into inflammatory diseases, providing insights into RIPK1-mediated signaling pathways and their role in inflammation and cell death. Its specificity and efficacy make it a suitable tool for investigating the therapeutic potential of RIPK1 inhibition in various disease models. -
RIPK2 PROTAC
RIP2 Kinase Inhibitor 4 is a selective inhibitor targeting the RIPK2 kinase via a PROTAC mechanism. This compound demonstrates significant potency with an IC50 value of 8 nM, effectively promoting the degradation of RIPK2. Additionally, it plays a role in inhibiting the release of TNF-α, making it valuable for research applications related to inflammatory diseases and immune response modulation. -
RIPK2 Inhibitor
RIPK2-IN-6 is a selective inhibitor of RIPK2, effectively blocking its phosphorylation and subsequently inhibiting the NF-κB and MAPK signaling pathways. This compound exhibits significant anti-inflammatory and anti-fibrotic properties, demonstrated in Dextran sodium sulfate-induced colitis models in mice. RIPK2-IN-6 is valuable in research exploring therapeutic strategies for inflammatory and fibrotic diseases. -
RIPK2 Inhibitor
RIPK2-IN-5 is a high-affinity inhibitor of receptor-interacting protein kinase 2 (RIPK2), demonstrating an IC50 value of 5.1 nM. This compound exhibits significant anti-inflammatory effects by reducing the secretion of TNF-α in response to MDP in a dose-dependent manner. With moderate stability in human liver microsomes, RIPK2-IN-5 serves as a valuable tool for investigating immune diseases and related therapeutic strategies. -
RIPK2 Inhibitor
RIPK2-IN-7 is a potent and selective inhibitor of RIPK2, exhibiting an IC50 of 0.6 nM. This compound effectively inhibits RIPK2 kinase activity, thereby disrupting the nucleotide-binding oligomerization domain (NOD) signaling pathway and decreasing the production of pro-inflammatory cytokines such as TNFα. RIPK2-IN-7 is a valuable tool for researching inflammatory bowel disease (IBD) and related inflammatory conditions. -
RIPK1 PROTAC Degrader
R1-ICR-5 is a selective RIPK1 PROTAC degrader designed to mediate protein degradation via the VHL pathway. This compound promotes the degradation of RIPK1, subsequently dysregulating TNFR1 and TLR3/4 signaling pathways, enhancing the activity of NF-κB, MAPK, and IFN signaling. Additionally, R1-ICR-5 facilitates RIPK3 activation, leading to necroptosis. This reagent is applicable in research focused on triple-negative breast cancer and skin inflammation. -
RIPK1 Binder
Ponicidin is a selective RIPK1 binder with an affinity of 135 nM for mouse RIPK1, functioning primarily as an apoptosis inducer and cell growth inhibitor. This compound modulates the JAK2/STAT3 signaling pathway to promote apoptosis, activates the PI3K/Akt pathway, and enhances SIRT1 expression. Additionally, Ponicidin exerts neuroprotective effects by alleviating oxidative stress, inhibiting inflammatory responses, and blocking necroptosis, while also increasing ROS production for antiproliferative and antiviral activity. It has significant implications for research in hepatocellular carcinoma, Alzheimer's disease, and gastric cancer. -
RIPK1 inhibitor
RIPK1-IN-36 is a potent inhibitor of receptor-interacting protein kinase 1 (RIPK1) with an EC50 of less than 25 nM. This compound is valuable for investigating the role of RIPK1 in various pathological conditions, including inflammatory diseases and neurodegenerative disorders. Researchers can utilize RIPK1-IN-36 to explore the therapeutic potential of targeting RIPK1 signaling pathways in relevant biological models. -
RIPK2 Inhibitor
CSLP43 is a selective inhibitor of RIPK2, demonstrating an IC50 of 19.9 nM against human RIPK2. By binding to the ATP-binding pocket of RIPK2, CSLP43 disrupts its interaction with the BIR2 domain of XIAP and cIAP1, effectively inhibiting RIPK2 ubiquitination and regulating NOD1- and NOD2-dependent inflammatory signaling pathways, as well as NF-κB activation. This compound is particularly relevant for research investigating Crohn's disease, Blau syndrome, early-onset sarcoidosis, and early-onset inflammatory bowel disease, due to its selectivity for the NOD1/NOD2 signaling pathway without affecting RIPK1 or RIPK3 activity. -
RIPK2/3 Inhibitor
RIPK2/3-IN-2 is a potent dual inhibitor of receptor-interacting protein kinases 2 and 3 (RIPK2 and RIPK3), exhibiting IC50 values of 12 nM and 18 nM, respectively. This compound effectively induces necroptosis, showcasing an EC50 value of 0.16 μM. RIPK2/3-IN-2 can be utilized in research exploring programmed cell death mechanisms and the role of necroptosis in various pathological conditions.
